This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Galantamine-Induced QTc Prolongation

Matthew W. Nelson, PharmD, BCPP, and Robert W. Buchanan, MD

Published: January 16, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Galantamine is an acetylcholinesterase inhibitor that is approved for the treatment of mild to moderate Alzheimer’s dementia. It may also have beneficial effects in the treatment of schizophrenia.1,2 The following is a case report of a patient with schizophrenia who developed corrected QT interval (QTc) prolongation while receiving galantamine.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 67

Quick Links: Dementia , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...